In recent years, the rapid development of next-generation sequencing (NGS) technologies
has led to a significant reduction in sequencing cost with improved accuracy. In the area of …

Genotyping tumor tissue in search of somatic genetic alterations for actionable information
has become routine practice in clinical oncology. Although these sequence alterations are …

Technological advancements in research on circulating biomarkers from patient derived
blood have enabled a less invasive means of diagnosing non-hematologic cancers …

There is a growing trend towards exploring the use of a minimally invasive “liquid biopsy” to
identify biomarkers in a number of cancers, including urologic malignancies. Multiple …

Cell-free DNA (cfDNA) refers to short fragments of acellular nucleic acids detectable in
almost all body fluids, including blood, and is involved in various physiological and …

The ability to study nonhematologic cancers through noninvasive sampling of blood is one
of the most exciting and rapidly advancing fields in cancer diagnostics. This has been driven …

Characterizing and monitoring tumor genomes with blood samples could achieve significant
improvements in precision medicine. As tumors shed parts of themselves into the circulation …

Clinical management of cancer patients could be improved through the development of
noninvasive approaches for the detection of incipient, residual, and recurrent tumors. We …

Cancers are caused by the accumulation of genomic alterations. Therefore, analyses of
cancer genome sequences and structures provide insights for understanding cancer …

More than 2% of adults harbor a pancreatic cyst, a subset of which progresses to invasive
lesions with lethal consequences. To assess the genomic landscapes of neoplastic cysts of …